Impax Labs, Tolmar enter collaboration agreement
HAYWARD, Calif., and FORT COLLINS, Colo. — Impax Labs has partnered with a pharmaceutical research, development, manufacturing and commercial operations company on a multiproduct agreement.
Impax Labs and Tolmar will develop, supply and distribute alternative dosage form products. The products and terms of the agreement were not disclosed; however, Impax Labs president and CEO Larry Hsu said the new agreement "represents an ideal extension of [our] initial product agreement."
"In the past two years, we have entered into four distinct partnerships for alternative dosage form products as we continue to execute our strategy of diversifying our product base," Hsu said. "Our business development activities will continue to focus on delivering growth from high-value products, technologies and businesses in complementary dosage forms."
Added Tolmar CEO Mike Duncan, "We are very pleased with this agreement. Tolmar is once again recognized as a key player in the specialty pharma space. This agreement is aligned with our long-term corporate strategy and we firmly believe that Impax is the right partner for these products."
McKesson completes Katz Group Canada pharmacy acquisition
SAN FRANCISCO — McKesson on Monday announced that it has completed the previously announced acquisition of the independent banner and franchise businesses of Katz Group Canada in an all-cash transaction that closed March 25.
McKesson in January agreed to acquire the Canadian company’s banner pharmacy business, Drug Trading, and its franchise pharmacy business, Medicine Shoppe Canada, in a deal worth approximately $926 million. Under the terms of the agreement, McKesson substantially will acquire all of the assets of Drug Trading, the shares of Medicine Shoppe Canada and a joint ownership interest in ProPharm’s pharmacy software application.
Katz’s banner and franchise operations will be integrated into McKesson’s Canadian pharmaceutical distribution and services business, which is part of McKesson’s Distribution Solutions segment.
McKesson Canada currently operates a number of banner groups, including Proxim, Associated Retail Pharmacy and Family Health Care Pharmacy.
Mobile health has high potential for growth, study finds
NEW YORK — The healthcare sector is thought to hold the most promise for mobile technology growth and development, according to a new survey by Deloitte.
Deloitte published results of a study, "Open Mobile: The growth era accelerates," which surveyed 250 senior executives from network carriers, mobile device manufacturers, software application developers and infrastructure component manufacturers, found that 78% of respondents considered health care and life sciences to have the most potential in stimulating business model innovation, along with retail and consumer products and financial services and commerce.
According to the study, wireless healthcare revenue, which was less than half a billion dollars in 2009, is projected to grow to more than $4 billion next year, and analysts expect the market for mobile health, or mHealth, to grow to about $4.6 billion by early 2014. Meanwhile, consumer products and retail are expected to experience "explosive" growth in the use of mobile technology.